Format

Send to

Choose Destination
Methods Mol Biol. 2018;1816:145-159. doi: 10.1007/978-1-4939-8597-5_11.

Cardiac Tissue Engineering Models of Inherited and Acquired Cardiomyopathies.

Author information

1
Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
2
Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. kevin.costa@mssm.edu.

Abstract

The lack of biomimetic in vitro models of the human heart has posed a critical barrier to progress in the field of modeling cardiac disease. Human engineered cardiac tissues (hECTs)-autonomous, beating structures that recapitulate key aspects of native cardiac muscle physiology-offer an attractive alternative to traditional in vitro models. Here we describe the use of hECTs to advance our understanding and modeling of cardiac diseases in order to test therapeutic interventions, with a focus on contractile dysfunction in the setting of inherited and acquired forms of cardiomyopathies. Four major procedures are discussed in this chapter: (1) preparation of hECTs from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) on single-tissue and multitissue bioreactors; (2) data acquisition of hECT contractile function on both of these platforms; (3) hECT modeling of hereditary phospholamban-R14 deletion-dilated cardiomyopathy; and (4) cryo-injury and doxorubicin-induced hECT models of acquired cardiomyopathy.

KEYWORDS:

Acquired cardiomyopathy; Contractility; Genetic cardiomyopathy; Models of disease; Stem cells; Tissue engineering

PMID:
29987817
PMCID:
PMC6561092
DOI:
10.1007/978-1-4939-8597-5_11
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center